SB Investment Advisers (uk) portfolio
Private equity or venture capitalPortfolio as of Jun 30, 2026 (Q2 2026) · filed with the SEC on Aug 14, 2026 · data updated on Nov 5, 2026 · Q2 2026 13F (filing) ↗ · all its 13F filings ↗
A 13F shows the portfolio at quarter-end and is filed up to 45 days later: these are not real-time positions and they may have changed.
SB Investment Advisers (uk) reported a $7.7 bn portfolio of 9 positions to the SEC as of the end of Q2 2026. Its largest positions are CPNG, GRAB, RLAY. During the quarter it exited Roivant Sciences.
Sections with a free account
What it reported after the quarter end (Q2 2026)
The 13F shows the portfolio as of Jun 30, 2026. Since then SB Investment Advisers (uk) has filed these own trades with the SEC (Form 4, when it owns more than 10% of a company or holds a role in it) and stakes above 5% (13D and 13G). It is not everything it did: only what it must report before the next 13F.
Form 4 · 6,000,000 shares · trade of Aug 25 · filed Aug 28, 2026 · filing ↗
What changed this quarter
3 positions with a change (2 trimmed, 1 sold). 1 is listed here: those of 0.5 points of the portfolio or more (up to 12).
- Roivant Sciences−1.0 ppof portfolioSold out1.0% → —
The figure on the right: for positions added to or trimmed, the change in the number of shares (%); for new and sold ones, the points of the portfolio moved (pp). Below, the portfolio weight before → after. Traded weight: what it bought or sold, excluding price effects.
Top holdings
- CoupangCPNG65.6%
- GRAB HoldingsGRAB19.8%
- Relay TherapeuticsRLAY6.8%
- CompassCOMP3.5%
- Vir BiotechnologyVIR1.5%
- Aurora InnovationAUR1.3%
- Energy Vault HoldingsNRGV1.0%
- Full Truck AllianceYMM0.6%
- Ginkgo Bioworks HoldingsDNA0.1%
“Since”: first quarter of the current run, unbroken until today. In the details, prices are the quarter-end prices of the quarters in which it added shares, per the 13F. The manager may have bought at any price within each quarter; the SEC only publishes the value at quarter end.
Portfolio by sector
- ● Consumer Discretionary 66%
- ● Industrials 20%
- ● Health Care 8%
- ● Real Estate 3%
- ● Information Technology 3%
How its portfolio changed (8 quarters)
Q2 2026: 9
Q2 2026: 100%
Q2 2026: 0.8%
Traded turnover: the weight it bought plus the weight it sold in the quarter, divided by two, excluding price moves. The plain “turnover” in the header does include that effect. With a free account: the full history and sectors over time.
13F filings with amendments or confidential positions
- 13F Q2 2025 ↗filed Aug 14, 2025Amendment of Nov 14, 2025 (replaces the original) ↗
Stakes above 5% (13D/13G)
Companies where this filer reported holding 5% or more of the shares. It is the figure from its latest filing on each one; history since December 2024.
How we classify it
Private equity or venture capital, per its Form ADV of Jun 24, 2026 (medium confidence).
The data, as reported: SB INVESTMENT ADVISERS (US) INC. (CRD 286323): 7.B private funds: 1 pe (gross assets $42.0 bn); 5.D assets by client type: pooled vehicles 100% (of $53.5 bn) · 13F: 97% of the portfolio was already held when the stock started trading
The type comes from a rule applied to that data. If it looks wrong, tell us.
Not counted as a concentrated manager: it is a private equity or venture firm; its stocks are usually holdings that went public. Its portfolio is shown all the same, but it is left out of manager counts, the consensus and the ranking. How this is decided
Managers of a similar size
A 13F portfolio value between a third and three times this one, whatever the type of filer. It is not a comparison of what they hold.
- Carmignac GestionInvestment firm · $7.7 bn
- Peconic PartnersInvestment firm · $7.5 bn
- AppaloosaInvestment firm · $7.5 bn
- Lyrical Asset ManagementInvestment firm · $7.9 bn
- Greenhaven AssociatesInvestment firm · $8.0 bn
- First Pacific AdvisorsInvestment firm · $8.0 bn